Sitryx Therapeutics, a biopharmaceutical company focused on immune cell metabolism, has announced significant leadership changes. Effective July 2, 2024, Iain Kilty will take over as CEO from Neil Weir, who becomes President and remains on the Board of Directors. Kilty, a former executive from Pfizer, brings over 25 years of experience in drug development and biotechnology. Weir, during his tenure, secured over $75 million in financing and forged a $1.1 billion licensing deal with Eli Lilly. Sitryx recently nominated its first clinical development candidate, SYX-5219, marking its transition to a clinical-stage company. SV Health Investors, the PE firm behind Sitryx, has expressed confidence in Kilty’s leadership to take the company to the next level, building on its strong scientific foundation and promising drug pipeline.
Biopharmaceuticals, Private Equity,United Kingdom, United States
https://svhealthinvestors.com/news/sitryx-announces-leadership-transition